title: Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.
abstract: Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer that has been the most common and most fatal cancer worldwide. Gefitinib (Iressa) and erlotinib (Tarceva) specific tyrosine kinase inhibitors (TKI) for the epidermal growth factor receptor (EGFR), have been demonstrated to be effective for some NSCLC patients and are pioneering molecular-targeted drugs used in the clinic for cancer. Because many studies indicate that only some patient populations benefit from these drugs, there has been an urgent need to develop diagnostic methods to select appropriate patients for whom treatment with these drugs will be beneficial. Moreover, problems of acquired resistance after long-term treatment with the drugs have emerged. In this review, I summarize the current understanding of the EGFR-activated signal transduction pathway, which plays important roles in tumorigenesis, and of the molecular mechanisms that determine the sensitivity toward EGFR-TKI.
authors: Division of Systems Biomedical Technology, Institute of Medical Science, University of Tokyo Tokyo, Japan. ngotoh@ims.utokyo.ac.jp
authors: Noriko
authors: N
authors: Gotoh
references: Cancer Res. 2006 Jan 15;66(2):944-50
references: 16424029
references: Clin Cancer Res. 2007 May 1;13(9):2795-803
references: 17473213
references: J Clin Oncol. 2005 Sep 1;23(25):5900-9
references: 16043828
references: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references: 11252954
references: Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
references: 16829981
references: Clin Cancer Res. 2006 Mar 1;12(5):1647-53
references: 16533793
references: PLoS Med. 2005 Jan;2(1):e17
references: 15696205
references: J Clin Oncol. 2005 Apr 10;23(11):2513-20
references: 15738541
references: N Engl J Med. 2005 Feb 24;352(8):786-92
references: 15728811
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Cancer Res. 2004 Dec 15;64(24):8919-23
references: 15604253
references: J Thorac Oncol. 2006 Sep;1(7):629-34
references: 17409929
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references: 15741570
references: Cancer Res. 2002 Dec 1;62(23):7001-3
references: 12460919
references: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references: 15870435
references: J Clin Oncol. 2005 Feb 1;23(4):857-65
references: 15681531
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387